Keine Story von Takeda Pharmaceutical Company Limited and Dainippon Sumitomo Pharma Co., Ltd. mehr verpassen.

Takeda Pharmaceutical Company Limited and Dainippon Sumitomo Pharma Co., Ltd.

24.01.2014 – 16:10

Dainippon Sumitomo Pharma and Takeda Receive Positive CHMP Opinion for Lurasidone - a New Atypical Antipsychotic Medication for Adults with Schizophrenia

Osaka, Japan (ots/PRNewswire) - Dainippon Sumitomo Pharma Co., Ltd. ("DSP") (Head Office: Osaka, Japan) and Takeda Pharmaceutical Company Limited ("Takeda") (Head Office: Osaka, Japan) today jointly announced that the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMA), has ...

mehr
25.10.2012 – 08:04

DSP and Takeda Announce the Acceptance of the European Medicines Agency Submission of an Atypical Antipsychotic Agent Lurasidone

Osaka, Japan (ots/PRNewswire) - Dainippon Sumitomo Pharma Co., Ltd. ("DSP") (Headquarters: Osaka, Japan) and Takeda Pharmaceutical Company Limited ("Takeda") (Headquarters: Osaka, Japan) today announced that the European Medicines Agency (EMA) has confirmed the acceptance for review of the Marketing Authorization ...

mehr

1